News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Construction is now underway with the facility scheduled to be operational by 2025
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
The WAVEsystem with the WAVEcontrol 4.0 embedded
Syngene's collaboration with Zoetis started in 2011
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Subscribe To Our Newsletter & Stay Updated
